BioSpace News Archive

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the fourth quarter and full year ended on December 31, 2021.

Kala Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.

Ocuphire Pharma, Inc. today announced positive topline results in the MIRA-3 trial, the company’s second Phase 3 registration trial investigating its product candidate Nyxol® for the reversal of pharmacologically-induced mydriasis (dilation of pupil).

Hosted by Dr. Neal Shore, Chief Medical Officer of Surgical Oncology and Urology with GenesisCare and director at Carolina Urologic Research Center, the interview series explores the new field of PSMA PET/CT imaging and its potential impact on the future of prostate cancer care.

Prelude Corporation announced today that its study in 926 patients demonstrating the clinical utility of DCISionRT and its Residual Risk Subtype (RRt) was selected for a scientific session oral presentation at the American Society of Breast Surgeons (ASBrS) 23rd Annual Meeting.

Lucira Health, Inc. announced that preliminary clinical study results for its COVID-19 & Flu test demonstrated similar sensitivity and specificity to highly sensitive lab-based PCR assays for COVID-19, Flu A, and Flu B.

Vector Laboratories today announced that Kum Ming Woo has joined its executive team as Vice President, Operations.

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release fourth quarter financial results for the three and twelve month period ended December 31, 2021 after markets close on Thursday, March 31, 2022.

Lipocine Inc. announced today that Antares Pharma, Inc. issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) has approved TLANDO™.

VectivBio Holding AG today presented new clinical data demonstrating the potential of apraglutide, a next-generation, long-acting GLP-2 analog, as a novel treatment for short bowel syndrome with intestinal failure (SBS-IF) patients who have impaired renal function.